financetom
Business
financetom
/
Business
/
Equity Bancshares Q2 Earnings, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Equity Bancshares Q2 Earnings, Revenue Rise
Jul 14, 2025 2:41 PM

05:17 PM EDT, 07/14/2025 (MT Newswires) -- Equity Bancshares ( EQBK ) reported Q2 earnings late Monday of $0.86 per diluted share, up from $0.76 a year earlier.

Analysts polled by FactSet expected $0.89.

Revenue for the quarter ended June 30, expressed as the sum of net interest income and total noninterest income, was $58.4 million, up from $55.4 million a year earlier.

Four analysts surveyed by FactSet expected $60.5 million.

Shares of Equity Bancshares ( EQBK ) were down 5.8% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Novavax (NVAX) Stock Is Rising
Why Novavax (NVAX) Stock Is Rising
Jan 7, 2025
Shares of Novavax Inc ( NVAX ) are trading higher by 13.5% to $11.09 during Tuesday’s session following a CDC report highlighting a sharp increase in respiratory illnesses across the U.S. The surge, attributed to higher cases of seasonal influenza, COVID-19, and RSV, has reignited interest in vaccine developers. Additionally, the Louisiana Department of Health this week reported the death...
Vertex, Orna Therapeutics Collaborate on Gene Editing Therapies for Sickle Cell Disease, Beta Thalassemia
Vertex, Orna Therapeutics Collaborate on Gene Editing Therapies for Sickle Cell Disease, Beta Thalassemia
Jan 7, 2025
10:43 AM EST, 01/07/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) has entered into a three-year research collaboration with Orna Therapeutics to develop gene editing therapies for sickle cell disease and transfusion-dependent beta thalassemia, Orna said Tuesday. The collaboration will use Orna's lipid nanoparticle delivery system to advance Vertex's therapeutic development, Orna said. Under the agreement, Orna said it...
Myriad Genetics Forms 5-Year Alliance With MD Anderson to Evaluate Molecular Residual Disease Assay
Myriad Genetics Forms 5-Year Alliance With MD Anderson to Evaluate Molecular Residual Disease Assay
Jan 7, 2025
10:40 AM EST, 01/07/2025 (MT Newswires) -- Myriad Genetics ( MYGN ) and the University of Texas MD Anderson Cancer Center said Tuesday that they formed a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular residual disease, or MRD, assay. Under the terms of the deal, the parties will collaborate to design studies that will...
BRIEF-US Steel CEO On Nippon Merger Says We Want Due Process To Work- CNBC
BRIEF-US Steel CEO On Nippon Merger Says We Want Due Process To Work- CNBC
Jan 7, 2025
Jan 7 (Reuters) - * US STEEL CEO ON NIPPON MERGER SAYS WE WANT DUE PROCESS TO WORK, WE HAVE A NEW PRESIDENT WHO WILL TAKE A FRESH LOOK AT THIS - CNBC * US STEEL CEO DAVID BURRITT ON NIPPON MERGER SAYS WE BELIEVE WE CAN CLOSE THE DEAL FASTER, THERE'S A NEW PRESIDENT IN THE HOUSE - CNBC...
Copyright 2023-2026 - www.financetom.com All Rights Reserved